scholarly journals Visualization and quantification of pancreatic tumor stroma in fresh tissue via ultraviolet surface excitation

2021 ◽  
Vol 26 (01) ◽  
Author(s):  
Phuong Vincent ◽  
Petr Bruza ◽  
Scott M. Palisoul ◽  
Jason R. Gunn ◽  
Kimberley S. Samkoe ◽  
...  
2012 ◽  
Author(s):  
Pippa Newell ◽  
Marka Crittenden ◽  
Talicia Savage ◽  
Benjamin Cottam ◽  
Paul Hansen ◽  
...  

2020 ◽  
Vol 4 (1) ◽  
pp. 26-39 ◽  
Author(s):  
Deby Fajar Mardhian ◽  
Aggelos Vrynas ◽  
Gert Storm ◽  
Ruchi Bansal ◽  
Jai Prakash

2020 ◽  
Vol 146 (12) ◽  
pp. 3233-3240
Author(s):  
Adrian M. Seifert ◽  
Julian List ◽  
Max Heiduk ◽  
Rahel Decker ◽  
Janusz von Renesse ◽  
...  

Abstract Introduction The immunosuppressive tumor microenvironment promotes progression of pancreatic ductal adenocarcinoma (PDAC). γδ T cells infiltrate the pancreatic tumor stroma and support tumorigenesis through αβ T cell inhibition. Pancreatic stellate cell (PSC) activation contributes to pancreatic fibrosis in PDAC, limiting the delivery and efficacy of therapeutic agents. Whether γδ T cells have direct effects on PSC activation is unknown. Methods In this study, we analyzed tumor tissue from 68 patients with PDAC and determined the frequency and location of γδ T cells using immunohistochemistry and immunofluorescence. PDAC samples from the TCGA database with low and high TRGC2 expression were correlated with the expression of extracellular matrix genes. Further, PSCs were isolated from pancreatic tumor tissue and co-cultured with γδ T cells for 48 hours and cytokine production was measured using a cytometric bead array. Results γδ T cells infiltrated the pancreatic tumor stroma and were located in proximity to PSCs. A high infiltration of γδ T cells was associated with increased expression of several extracellular matrix genes in human PDAC. In vitro, γδ T cells stimulated IL-6 production by PDAC-derived PSCs. Conclusion γδ T cells activated PSCs and modulation of this interaction may enhance the efficacy of combinational therapies in human PDAC.


2010 ◽  
Author(s):  
Frank F. Shi ◽  
Liam Campion ◽  
Elizabeth Kaiser ◽  
Catherine Ferrante ◽  
Diana Wiley ◽  
...  

2018 ◽  
Vol 10 (1-2) ◽  
pp. 1-10 ◽  
Author(s):  
Bradley R. Hall ◽  
Andrew Cannon ◽  
Christopher Thompson ◽  
Bindu Santhamma ◽  
Alejandra Chavez-Riveros ◽  
...  

Pharmaceutics ◽  
2022 ◽  
Vol 14 (1) ◽  
pp. 128
Author(s):  
Andrew Gdowski ◽  
Hamed Hayatshahi ◽  
Rafal Fudala ◽  
Rohan Joshi ◽  
Jin Liu ◽  
...  

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies and is the fourth leading cause of cancer-related deaths in the United States. Unfortunately, 80–85% of patients are diagnosed with unresectable, advanced stage tumors. These tumors are incurable and result in a median survival less than approximately six months and an overall 5-year survival rate of less than 7%. Whilst chemotherapy is a critical treatment, cure is not possible without surgical resection. The poor clinical outcomes in PDAC can be partially attributed to its dense desmoplastic stroma, taking up roughly 80% of the tumor mass. The stroma surrounding the tumor disrupts the normal architecture of pancreatic tissue leading to poor vascularization, high intratumoral pressure along with hypoxia and an acidic tumor microenvironment. This complicated microenvironment presents a significant challenge for drug delivery. The current manuscript discusses a novel approach to overcome many of these various obstacles. A complex of gemcitabine (GEM) and hemoglobin S (HbS) was formulated, which self-polymerizes under hypoxic and acidic conditions. When polymerized, HbS has the potential to break the tumor stroma, decrease intratumoral pressure, and therefore improve the treatment efficacy of standard therapy. Intratumoral injection of HbS with a fluorescent small molecule surrogate for GEM into a pancreatic tumor xenograft resulted in improved dissemination of the small molecule throughout the pancreatic tumor. The self-polymerization of HbS + GEM was significantly more effective than either agent individually at decreasing tumor size in an in vivo PDAC mouse model. These findings would suggest a clinical benefit from delivering the complex of GEM and HbS via direct injection by endoscopic ultrasound (EUS). With such a treatment option, patients with locally advanced disease would have the potential to become surgical candidates, offering them a chance for cure.


2017 ◽  
Vol 108 (11) ◽  
pp. 2156-2165 ◽  
Author(s):  
Takeshi Sato ◽  
Wataru Shibata ◽  
Yohko Hikiba ◽  
Yoshihiro Kaneta ◽  
Nobumi Suzuki ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document